RecruitingPhase 1Phase 2NCT07595172

NALIRIFOX+Adebrelimab+PULSAR for Advanced Pancreatic Cancer

A Phase I/II Clinical Trial of NALIRIFOX Combined With Adebrelimab and PULSAR as First-Line Treatment for Locally Advanced Unresectable or Metastatic Pancreatic Ductal Adenocarcinoma

Sponsor

West China Hospital

Enrollment

55 participants

Start Date

Apr 1, 2026

Study Type

INTERVENTIONAL

Conditions

Locally advanced and metastatic pancreatic cancer Pancreatic Ductal Adenocarcinoma (PDAC)

Summary

This study aims to evaluate the safety and preliminary efficacy of NALIRIFOX combined with adebrelimab and PULSAR as first-line treatment for locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC). Additionally, it will explore potential predictive and efficacy-related biomarkers.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called NALIRIFOX+Adebrelimab and PULSAR for people with locally advanced and metastatic pancreatic cancer and pancreatic ductal adenocarcinoma (pdac). The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.